Sponsors (22)
The bill improves patient safety by making common food allergens and specific gluten-containing grains in medicines clear, reducing accidental exposures, but imposes compliance costs and transitional uncertainty that could raise prices or strain smaller manufacturers and providers.
People with food allergies, celiac disease, or gluten sensitivity will be able to identify when a medicine contains or is derived from major food allergens or which gluten-containing grain is present, reducing the risk of allergic or autoimmune reactions.
Medicare, Medicaid beneficiaries and other patients may experience fewer accidental exposures and emergency visits because clearer labeling helps avoid harmful medication choices, lowering some healthcare utilization and associated costs.
Smaller drug makers and compounders will face added testing, verification, and relabeling compliance costs and administrative burdens that could reduce product availability or drive some firms out of certain markets.
Drug manufacturers generally will incur costs to update labeling and compliance processes, costs that could be passed on to consumers through higher drug prices or reduced affordability.
If federal implementation guidance is delayed or inconsistent, hospitals, pharmacies, and health systems may face uncertainty about which products comply during the transition, complicating procurement and dispensing decisions.
Based on analysis of 2 sections of legislative text.
Requires human drug labels to disclose any major food allergen or gluten-containing grain ingredient and identify each such ingredient and the type of grain if applicable.
Official title: To amend the Federal Food, Drug, and Cosmetic Act to require the label of a drug intended for human use to identify each ingredient in such drug that is, or is derived directly or indirectly from, a major food allergen or a gluten-containing grain, and for other purposes.
Introduced June 6, 2025 by Kelly Morrison · Last progress June 6, 2025
Requires pharmaceutical labels for human-intended drugs to disclose if they contain or are derived from a major food allergen or a gluten-containing grain (wheat, barley, rye, or crossbred hybrids). Labels must identify each such ingredient and, when applicable, the specific gluten-containing grain type. The labeling rule takes effect on the earlier of a Secretary of HHS‑determined date or two years after enactment.